Stay updated with breaking news from Abou Farhat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.
Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.
Next-generation sequencing analysis suggests that revising cancer care guidelines could allow 6,000 more cancer patients each year to benefit from immunotherapy.